ATNF (180 Life Sciences) Cash Flow from Financing : $0.46 Mil (TTM As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is 180 Life Sciences Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2024, 180 Life Sciences paid $0.00 Mil more to buy back shares than it received from issuing new shares. It spent $0.48 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, 180 Life Sciences spent $0.48 Mil on financial activities for the three months ended in Sep. 2024.

180 Life Sciences Cash Flow from Financing Historical Data

The historical data trend for 180 Life Sciences's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

180 Life Sciences Cash Flow from Financing Chart

180 Life Sciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

3.94

-8.73

25.41

10.87

5.91

180 Life Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash Flow from Financing	Get a 7-Day Free Trial															2.45	1.47	-0.26	-0.27	-0.48

180 Life Sciences Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

180 Life Sciences's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	5.999	+	0	+	-0.288	+	0	+	0	+	0.197
=	5.91

180 Life Sciences's Cash from Financing for the quarter that ended in Sep. 2024 is:

	Cash Flow from Financing		(Q: Sep. 2024 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	-0.476	+	0	+	0	+	0
=	-0.48

Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.46 Mil.

180 Life Sciences (NAS:ATNF) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

180 Life Sciences's issuance of stock for the three months ended in Sep. 2024 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

180 Life Sciences's repurchase of stock for the three months ended in Sep. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

180 Life Sciences's net issuance of debt for the three months ended in Sep. 2024 was $-0.48 Mil. 180 Life Sciences spent $0.48 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

180 Life Sciences's net issuance of preferred for the three months ended in Sep. 2024 was $0.00 Mil. 180 Life Sciences paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

180 Life Sciences's cash flow for dividends for the three months ended in Sep. 2024 was $0.00 Mil. 180 Life Sciences received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

180 Life Sciences's other financing for the three months ended in Sep. 2024 was $0.00 Mil. 180 Life Sciences received $0.00 Mil on other financial activities.

180 Life Sciences Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of 180 Life Sciences's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

180 Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 180 Life Sciences Corp (NAS:ATNF) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA, USA, 94306

Website

https://www.180lifesciences.com

180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.

Executives

James N. Woody	director, officer: Chief Executive Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Marc Feldmann	director	5 DURHAM TERRACE, LONDON X0 W25PB
Lawrence Steinman	director	10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Mcgovern Jr. Donald A.	director	C/O CARS.COM, 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Quan Anh Vu	officer: COO / Chief Business Officer	22616 ERWIN STREET, WOODLAND HILLS CA 91367
Ozan Pamir	officer: Interim CFO	2443 FILLMORE ST #380-17649, SAN FRANCISCO CA 94115
Pamela G Marrone	director	C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618
Teresa Deluca	director	40 BURTON HILLS BOULEVARD, SUITE 500, NASHVILLE TN 37215
Russell T Ray	director	2525 DUPONT DR, IRVINE CA 92612
Knuettel Ii Francis	director	205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
Marlene Krauss	director, 10 percent owner, officer: Chief Executive Officer	C/O KBL HEALTHCARE INC, 645 MADISON AVE, NEW YORK NY 10022
Lawrence Marshall Gold	director	830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025
Jonathan B. Rothbard	officer: Chief Scientific Officer	501 BEALE STREET, UNIT 8D, SAN FRANCISCO CA 94105
Shoshana Shendelman	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Richard W Barker	director	290 COMMONWEALTH AVENUE #17, BOSTON MA 02115